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Introduction {#sec001}
============

Proper neuronal function necessitates a highly regulated extracellular environment in the brain. Accumulation of interstitial solutes, such as amyloid β and toxic compounds \[[@pone.0229702.ref001]\] may lead to degenerative diseases, such as Alzheimer's disease \[[@pone.0229702.ref002],[@pone.0229702.ref003]\] or even autism \[[@pone.0229702.ref004]\]. Although the Blood Brain Barrier is thought to be the primary mechanism involved in controlling the brain blood-exchange, the existence of a fluid driven transport system (so-called glymphatic system) via cerebrospinal fluid (CSF) or interstitial fluid (ISF) has been proposed recently as a waste clearance system through the perivascular and interstitial spaces in the brain \[[@pone.0229702.ref001],[@pone.0229702.ref005]\]. Hypothetically, CSF crosses the astrocyte end-feet bound to arteries in the perivascular space \[[@pone.0229702.ref006],[@pone.0229702.ref007]\]. After washing the interstitial space, the resulting ISF is flushed back outside the brain via veins in the perivascular space. Several factors play a crucial role in the modulation of this clearance system activity, notably sleep and anesthesia, perhaps via a modulation of brain blood volume and pressure \[[@pone.0229702.ref008]--[@pone.0229702.ref011]\]. This scheme gives astrocytes a crucial role in controlling water movements between the blood and the brain, through a mechanism dependent on Aquaporin-4 (AQP4), a membrane-bound water channel expressed at their end-feet \[[@pone.0229702.ref012],[@pone.0229702.ref013]\]. AQP4 is involved in the rapid volume regulation of astrocytes \[[@pone.0229702.ref014]\] and deletion of the AQP4 gene suppresses the clearance of soluble amyloid β \[[@pone.0229702.ref001]\].

Although most studies have been performed *in vitro*, some studies have shown astrocyte volume changes *in vivo* using 2-photon microscopy. Acute osmotic and ischemic stress induce astrocyte volume changes *in vivo* mice \[[@pone.0229702.ref015]\], and Thrane et al showed that the astrocyte volume change induced by osmotic stimulation was inhibited in AQP4 KO mice \[[@pone.0229702.ref016]\]. Overall, such studies suggest that dynamic volume change of astrocytes, through water flux mediated by AQO-4 channels may be associated with CSF flow regulation. Actually, astrocytes end-feet are involved in the CSF/ISF exchanges in perivascular space during sleep/awake cycle \[[@pone.0229702.ref017]\].

Recently MRI has been proposed as a more versatile approach to investigate the glymphatic system in vivo, using intrathecal or intravenous injections of gadolinium-based contrast agents (GBCAs) as tracers \[[@pone.0229702.ref007],[@pone.0229702.ref018]\]. However, this approach remains invasive and, paradoxically, gadolinium has been shown to deposit in the brain \[[@pone.0229702.ref019],[@pone.0229702.ref020]\] possibly in relation to a lack of brain drainage \[[@pone.0229702.ref010]\]. Therefore, alternative methods are needed to investigate the glymphatic system non-invasively, especially in the human brain. Fluid-dynamics driven and BOLD fast MRI have the potential to evaluate CSF pulsations in the ventricles and hemodynamics \[[@pone.0229702.ref011],[@pone.0229702.ref021],[@pone.0229702.ref022]\], while IVIM and diffusion MRI have been shown as promising methods for the evaluation of the ISF \[[@pone.0229702.ref007],[@pone.0229702.ref023]--[@pone.0229702.ref027]\].

Those considerations led us to investigate whether diffusion MRI was sensitive to astrocyte activity and, in turn, could become a marker of the overall glymphatic system. Diffusion MRI is exquisitely sensitive to changes in tissue microstructure, notably cell swelling \[[@pone.0229702.ref028]\]. Diffusion MRI is, for instance, sensitive to astrocyte swelling induced in rodents \[[@pone.0229702.ref029]\]. Hence, we hypothesized that dynamic changes in astrocytes activity and related volume changes could be monitored directly and non-invasively with diffusion MRI. To test this hypothesis we monitored variations of new diffusion MRI markers, namely the Sindex and the sADC, which have been tailored to increase sensitivity to tissue microstructure through water diffusion hindrance \[[@pone.0229702.ref030],[@pone.0229702.ref031]\] upon acute inhibition of astrocyte AQP4 channels in a mouse brain model using 2-(nicotinamide)-1,3,4-thia-diazole (TGN-020), a compound that blocks AQP4 channels *in vivo* in the mouse brain \[[@pone.0229702.ref032]\].

Material and methods {#sec002}
====================

Animal preparation {#sec003}
------------------

Thirty-two male C57BL6 mice (16--28 g, 4--10 weeks, Charles River, France) were allocated to two groups. The choice of a mouse brain model was motivated by prospect of using our protocol later to AQP-4 knock-out mice. First, for the TGN-020 group, 16 mice received an intra-peritoneal injection of 250mg/kg TGN-020 diluted in a gamma-cyclodextrine solution (10 mM) in order to increase its solubility. Second, for the control group, sixteen mice received an intra-peritoneal injection of the vehicle solution only (10 mM gamma-cyclodextrine in saline). The mice were housed on a 12-hour light-dark cycle and fed standard food ad libitum. Anesthesia was induced using 3% isoflurane in a mix of air and oxygen (air: 2 L/min, O2: 0.5 L/min). Then, 0.015 mg/kg of dexmedetomidine was administered intraperitoneally and followed by a continuous infusion of 0.015 mg/kg/h via subcutaneous catheter and maintained isoflurane at 0.8%.

Throughout the acquisition, the animals' body temperature was maintained between 36.5 and 37.0 °C using heated water (Grant TC120, Grant Instruments, Shepreth, UK). To avoid motion-related artifacts the head was immobilized using a bite bar and ear pins. The respiration rate was monitored and stable (60--90 /min) throughout the experiment.

All animal procedures used in the present study were approved by an institutional Ethic Committee (Comité d'Ethique en Expérimentation Animale, Commissariat à l'Energie Atomique et aux Énergies Alternatives, Direction des Sciences du Vivant (Fontenay-aux-Roses, France)) and by Ministère de l'Education Nationale, de l'Enseignement Supérieur et de la Recherche (France) (reference APAFIS\#8462-2017010915542122v2) and were conducted in strict accordance with the recommendations and guidelines of the European Union (Directive 2010/63/EU). This manuscript is in compliance with the ARRIVE guidelines (Animal Research: Reporting in Vivo Experiments) on how to REPORT animal experiments.

MRI experiments {#sec004}
---------------

The MRI experiments were conducted on a Bruker 11.7T scanner (Bruker BioSpin, Ettlingen, Germany) equipped with a gradient system allowing a maximum gradient strength of 760 mT/m. A cryo-cooled mouse brain coil was used. Animal positioning was performed using multi-slice fast low angle shot imaging (FLASH, TE/TR  =  2.3/120 ms). A global first and second order shim was achieved followed by a local second order shim over the brain parenchyma. Structural (anatomical) images were acquired with the following parameters: T2 TurboRARE sequence, TE/TR = 11.15/2500 ms. Diffusion-weighted echo-planar imaging (DW-EPI) data sets were acquired with the following parameters: 150x150x250 μm^3^ resolution, 3 b-values (0, 250, 1750) s/mm^2^ along 6 directions, NA = 4, TE/TR = 36.3/2300 ms, 18 slices, diffusion time = 24 ms, total scan time = 5 min. The area covered by the 18 slices of the scans encompassed 5 mm in the axial plane with the center of the slab positioned at the middle of the brain. Six DW-EPI sets were first acquired (baseline) before TGN-020 or vehicle was injected. Then, after the injection, 12 additional DW-EPI data sets were acquired ([Fig 1](#pone.0229702.g001){ref-type="fig"}) every 5 minutes.

![Schematic figure of MRI experiment protocol.\
The vertical arrow indicates the saline or TGN-020 injection. DWI, diffusion weighted MRI; NR, number of repetitions. Horizontal arrow indicates the timeline.](pone.0229702.g001){#pone.0229702.g001}

Data processing {#sec005}
---------------

### Preprocessing {#sec006}

Regions of interest (ROIs) were originally created using the Allen Brain Atlas \[[@pone.0229702.ref033]\] and registered to a mouse brain MRI template to create a labeled atlas. We referred to previous studies based on microscopy \[[@pone.0229702.ref034]\] to assess the vascular distribution within the selected brain structures. The atlas was then co-registered with the b = 0 images of the first scans for each subject, and not the other way around to avoid changing raw voxel signals. Those preprocessing steps, also including radiofrequency bias field correction \[[@pone.0229702.ref035]\] and denoising were performed using ANTs (<https://stnava.github.io/ANTs/>) \[[@pone.0229702.ref036]\] ([Fig 2](#pone.0229702.g002){ref-type="fig"}). We assumed geometric distortion to be negligible; this condition was qualitatively checked on several mice for all b values. Furthermore, the standard-deviation of the signal intensity across scans was evaluated for each b value and each voxel (after Gaussian smoothing) was estimated as a marker of motion or instability. A threshold of 4% was used to flag unstable voxels. Data sets were at least one of the ROIs contained flagged voxels were discarded.\[[@pone.0229702.ref037]\].

![Example of ROI registration with ANTs on a mouse brain.](pone.0229702.g002){#pone.0229702.g002}

### DWI analysis {#sec007}

First, a shifted ADC (sADC) was computed using signal acquired at two key b values (instead of the standard values of 0 and 1000s/mm^2^), chosen to optimize signal sensitivity to both Gaussian and non-Gaussian diffusion which is more sensitive to tissue microstructure through hindrance effects \[[@pone.0229702.ref030],[@pone.0229702.ref031]\]. $$sADC = \frac{\ln\left( \frac{S_{Lb}}{S_{Hb}} \right)}{Hb - Lb}$$ where Lb is the low key b value (250s/mm^2^), Hb the high key b value (1750 s/mm^2^), S~Lb~ the signal at low key b value and S~Hb~ the signal at high key b value.

Second, data were analyzed using the Sindex method \[[@pone.0229702.ref031]\]. The Sindex diffusion marker has been designed to identify tissue types or conditions based on their microstructure \[[@pone.0229702.ref031]\]. The Sindex was calculated from the direction-averaged, normalized signals, S~V~(*b*) in each voxel, as the algebraic relative distance between the vector made of these signals and those of 2 signature tissue signals S~A~ in condition A, and S~B~ in condition B, at each key b value as \[[@pone.0229702.ref031]\]: $$SI(V) = \left\{ {{\max\left( {\frac{\left\lbrack {{dS}_{V}\left( {Hb} \right) - {dS}_{V}\left( {Lb} \right)} \right\rbrack}{\left\lbrack {{dS}_{B}\left( {Hb} \right) - {dS}_{B}\left( {Lb} \right)\rbrack} \right.},0} \right)} - \left\lbrack {{\max\left( \frac{\left\lbrack {{dS}_{V}\left( {Hb} \right) - {dS}_{V}\left( {Lb} \right)} \right\rbrack}{\left\lbrack {{dS}_{A}\left( {Hb} \right) - {dS}_{A}\left( {Lb} \right)} \right\rbrack} \right.},0} \right)} \right\}$$ with dS~V~,~A,B~(*b*) = \[S~V~,~A,B~(*b*)- S~N~(*b*)\]/S~N~(*b*). S~N~ is taken as an intermediate signal between S~A~ and S~B~. SI was then linearly scaled as *Sindex* = (SI+1)\*25+25 to be centered at 50. A tissue with status similar to condition A has *Sindex* = 75, while for a status similar to condition B one has *Sindex* = 25. The library of the 2 reference diffusion MRI signals was built in advance from previously acquired data, one representing a generic mouse brain tissue (B) and another derived by simulating a moderate increase in diffusion hindrance (A) using the Kurtosis diffusion model \[[@pone.0229702.ref031]\]. For this study, S~A~(Lb) = 0.858; S~A~(Hb) = 0.370; S~B~(Lb) = 0.855; S~B~(Hb) = 0.317. Obviously the Sindex is expected to vary widely across brain regions according to their degree of diffusion hindrance ([Fig 3](#pone.0229702.g003){ref-type="fig"}), for instance white matter regions have higher Sindex values than gray matter regions. However, our focus was on the local changes in Sindex values induced by the injection of TGN-020, reflecting local changes in the degree of diffusion hindrance (a decrease in Sindex reflecting a decrease in hindrance). Sindex and sADC were calculated on a voxel-by-voxel basis to generate parametric maps. Calculation was also performed on a ROI level, averaging signals from all voxels within the ROI. ROIs were placed over the cerebral cortex, the striatum and the hippocampus (whole hippocampus, CA3 region and dentate gyrus, DG). The hippocampus is known to be reached in AQP4 expression \[[@pone.0229702.ref038],[@pone.0229702.ref039]\].

![**Sindex (first row) maps and sADC (second row) maps for a representative mouse from vehicle group (first column) and from TGN-020 group (right column).** These maps were obtained by averaging the 6 last time points.](pone.0229702.g003){#pone.0229702.g003}

Values obtained before (6 first scans) and after injection (6 last scans) were averaged in each ROI for each animal. The parameter time course was also calculated by averaging 3 successively acquired datasets (resulting in six time points with a resolution of 15 minutes) for each animal. Before averaging across individual subjects, we performed an outlier exclusion using a z-score filter (z\>3) calculated over the subject's parameter values for each time point.

Statistical analysis {#sec008}
--------------------

The statistical tests were performed in python (Python Software Foundation. Python Language Reference, version 3.7. Available at [http://www.python.org](http://www.python.org/)). We performed a paired two sample t-test between pre and post-injection data in each group and a pair-wise t-test with a posthoc correction for multiple comparison to compare the post-injection data between two groups and the pre-injection data between two groups.

For the time course data, we performed a two sample t-test between the two groups for each time point.

Results {#sec009}
=======

Averaged Sindex and sADC following vehicle or TGN-020 injection {#sec010}
---------------------------------------------------------------

[Fig 3](#pone.0229702.g003){ref-type="fig"} shows brain maps of Sindex and sADC for a representative mouse following vehicle and TGN-020 injection. Differences between the two conditions are readily visible with a decrease in Sindex and an increase in sADC following TGN-20 injection. Those changes are quantitatively assessed in [Fig 4](#pone.0229702.g004){ref-type="fig"}. [Fig 4A--4C](#pone.0229702.g004){ref-type="fig"} show the Sindex averaged over six scans before and after the injection in different locations, i.e., cerebral cortex, hippocampus and striatum, in vehicle and the TGN-020 group. TGN-020 injection resulted in significant decrease in Sindex in the cortex (p = 0.0061) and the hippocampus (p = 0.00069) but not in the striatum (p = 0.26). No significant change of Sindex was observed following vehicle injection in those locations (p = 0.94 in cortex, p = 0.85 in hippocampus and p = 0.14 in striatum). [Fig 4D--4F](#pone.0229702.g004){ref-type="fig"} show the sADC averaged over six scans before and after the injection in the same locations as for the Sindex, in vehicle and TGN-020 group. TGN-020 injection resulted in significant increase in sADC in the cortex (p = 0.0064) and the hippocampus (p = 0.00068) but not in the striatum (p = 0.26). No significant change of sADC was observed following vehicle injection in any of the ROIs considered (p = 0.91 in cortex, 0.78 in hippocampus and 0.14 in striatum). We also investigated subregions of the hippocampus CA3 and DG ([S1 Fig](#pone.0229702.s001){ref-type="supplementary-material"}). The TGN-020 injection significantly decreased Sindex and increased sADC values both in the DG and the CA3 (Sindex in DG: -11.8, p = 4.8e-7 and in CA3: -4.8, p = 0.00012; sADC in CA3: +10.2, p = 0.00013, sADC in DG: +22.5, p = 7.14e-7). However, the baseline for Sindex and sADC in DG was found noisy and not stable ([S1B and S1F Fig](#pone.0229702.s001){ref-type="supplementary-material"}) due to the smaller size of DG resulting in a very low voxel count compared to the other ROIs (voxel count for DG, CA3, hippocampus, striatum, cortex were 85, 181, 763, 2069 and 8270, respectively).

![Boxplot of Sindex and sADC in the cortex (a: Sindex, d: sADC), the striatum (b: Sindex, e: sADC) and hippocampus (c: Sindex, f: sADC). Left, Vehicle group; right TGN-020 group in each figure. Pre, pre-injection (light blue); post, post-injection (dark blue) of vehicle or TGN-020 group. \*: p\<0.05, \*\*: p\<0.01, \*\*\*: p\<0.001 are the result for the paired t-test between pre and post-injection for each group. +: p\<0.05, ++: p\<0.01, +++: p\<0.001 are the result for a t-test with posthoc correction for multiple comparison between post-injection of the two groups. Diamonds represent outliers, a point is defined as an outlier if its value is below Q1--1.5×IQR or above Q3 + 1.5×IQR, where Q1 is the first quartile, Q3 the third quartile and IQR the interquartile range.](pone.0229702.g004){#pone.0229702.g004}

Sindex and sADC time courses following vehicle or TGN-020 injection {#sec011}
-------------------------------------------------------------------

We then investigated the time course of the Sindex and sADC for each group. The same ROIs were used as for the averaged Sindex and sADC values. [Fig 5A--5C](#pone.0229702.g005){ref-type="fig"} represents the Sindex time course for each ROI. A decrease of Sindex was observed after the injection of TGN-020 but not with vehicle injection in all ROIs. The Sindex significantly decreased (around 9% in the cortex) following TGN-020 injection in all ROIs and continued until the end of the scanning period. [Fig 5D--5F](#pone.0229702.g005){ref-type="fig"} show the sADC time course with an opposite trend compared to Sindex in all ROIs.

![Time course of Sindex and sADC in the cortex (a: Sindex, d: sADC), the striatum (b: Sindex, e: sADC) and hippocampus (c: Sindex, f: sADC). Blue line is vehicle group and orange line is TGN-020 group. Error bar shows standard deviation. The dashed line represents the injection time. +: p\<0.05, ++: p\<0.01, +++: p\<0.001 by two sample t-test between the two groups for each time point.](pone.0229702.g005){#pone.0229702.g005}

Discussion {#sec012}
==========

Several studies have underlined the potential of Diffusion MRI to investigate the glymphatic system \[[@pone.0229702.ref007],[@pone.0229702.ref023]--[@pone.0229702.ref025]\]. Astrocytes are considered to play a key role in brain waste clearance through membrane AQP4 channels expressed at their end-feet \[[@pone.0229702.ref012]\]. The ADC has been proposed as a biomarker of AQP gene expression, as earlier studies have demonstrated that the ADC obtained with high b values was correlated with the amount of increasing expression of AQP1 in glioblastoma cell lines \[[@pone.0229702.ref040]\]. In this study, we have investigated whether two diffusion MRI markers more sensitive to tissue microstructure than the ADC, namely the Sindex and sADC, could reveal changes in astrocyte activity induced by TGN-020.

Following AQP4 channel inhibition with a TGN-020 solution a decrease in Sindex and increase in sADC were readily observed in the cortex, more in the hippocampus, but not in the striatum, reflecting local differences in astrocyte \[[@pone.0229702.ref041]\] and vascular density \[[@pone.0229702.ref034]\]. In the hippocampus changes in Sindex and sADC were larger in DG than in CA3 layer, presumably in line with differences in AQP4 channels expression on astrocytes \[[@pone.0229702.ref039]\]. However, further validation is required as the baseline Sindex and sADC values were not stable due to the small count in the DG ROI (see [Result](#sec009){ref-type="sec"}). Histological studies would also confirm differences in astrocyte density and volume. Nonetheless, those results suggest that diffusion MRI is sensitive to astrocyte activity and, indirectly, to the status of the glymphatic system. Those diffusion MRI markers provide a higher sensitivity to small changes in tissue features by encompassing in a single marker Gaussian and non-Gaussian diffusion effects. Furthermore they are easy to calculate and are not diffusion signal model dependent, such as the kurtosis model \[[@pone.0229702.ref031]\]. The low key b value used in this study was high enough (250 s/mm^2^) to make perfusion-related IVIM effects negligible. Hence the observed changes in the diffusion markers reflect genuine tissue microstructure related diffusion effects and not perfusion effects (cerebral blood flow) which have already been reported observed with TGN-020 \[[@pone.0229702.ref042]\]. Indeed, acquisition of perfusion-driven IVIM data could be valuable to get information on the vascular distribution which is known to vary across brain structures \[[@pone.0229702.ref034]\], but this was not possible within our protocol timeframe to guaranty animal stability.

The Sindex decrease and the sADC increase jointly point out to a decrease in the amount of hindrance for water diffusion in astrocyte rich areas (cortex and hippocampus) under acute AQP4 channel inhibition induced by TGN-20. Based on established diffusion MRI mechanisms \[[@pone.0229702.ref028]\] this hindrance decrease suggests an astrocyte volume reduction \[[@pone.0229702.ref043],[@pone.0229702.ref044]\] associated with an increase of the ISF (were diffusion is tortuous) \[[@pone.0229702.ref045]\] or an increase in astrocyte membrane permeability and water exchange. Indeed, astrocytes rapidly regulate their volume throughout AQP4 channels. Those results obtained by acute AQP4 inhibition contrast earlier reports using chronic models, such as an ADC decrease observed during AQP4 inhibition with interfering RNA \[[@pone.0229702.ref046]\] or change in ADC in AQP4 knockout mice \[[@pone.0229702.ref047]\]. Beside the higher sensitivity to tissue microstructure of the sADC over the ADC, such discrepancy could possibly result from the modified astrocyte phenotype associated with a long-term inhibition of AQP4 expression found in those previous studies \[[@pone.0229702.ref048]\]. The sub-acute or chronic inhibition of AQP4 activity by AQP4-antibodies or small interfering RNA duplexes alter astrocyte morphology and decrease water permeability \[[@pone.0229702.ref049],[@pone.0229702.ref050]\] which could result in an ADC decrease. Also, the effects we observed in baseline conditions should be distinguished from those obtained in conditions of neuronal activation for which AQP4 inhibition by extracellular acidification results in astrocyte swelling, capillary lumen expansion and Virchow-Robin space reduction \[[@pone.0229702.ref051]\]. Further studies should aim at precising the mechanisms involved in the observed effects, however histology would require the brain to be fixed, preventing astrocyte volume changes to be monitored before and after TGN-020/saline injection within the same animal. In vivo fluorescent imaging could be used, but only in the cortex. Clearly, the detailed mechanisms underlying acute AQP4 channel inhibition by TGN-20 and chronic AQP4 knockout mice models are lacking. Diffusion MRI has the potential to clarify those mechanisms, notably through non-Gaussian diffusion markers, such as the Sindex and the sADC. Fractional anisotropy (FA) measurements results were not reported as they are relevant only to areas exhibiting diffusion anisotropy, ie, white matter given the spatial resolution of our images. Beside, due to noise FA values are highly corrupted and often reflect mainly variations in underlying ADC (here sADC) \[[@pone.0229702.ref052]\].

Another issue to consider is that our studies were obviously performed under anesthesia. Anesthetic drugs are known to impact intracranial pressure, which could interfere with CSF-ISF exchanges. For instance, dexmedetomidine and ketamine enhance CSF influx alongside perivascular spaces \[[@pone.0229702.ref053]\]. Moreover, similar to what happens during sleep, anesthesia is associated with a substantial increase in both perivascular and extracellular space volume \[[@pone.0229702.ref054]\]. Thus, it would be interesting to check whether the effects we have observed with TGN-20 persist in awake animals. A recent study has shown that, while the baseline ADC did not change between anesthetic and awake conditions, DOTA-Gd accumulation was significantly suppressed during anesthesia in contrast enhanced MRI \[[@pone.0229702.ref055]\].

Conclusion {#sec013}
==========

Work remains to better understand the mechanisms involved in brain waste clearance through a so-called glymphatic system and the contribution of astrocytes to this system. The reference method to investigate the glymphatic system in preclinical settings relies on the intracisternal injection of gadolinium in the cisterna magna \[[@pone.0229702.ref056]\]. Our results show that changes in astrocyte activity thought to regulate CSF-ISF exchanges, an important component of glymphatic system functionality, could be monitored non-invasively with diffusion MRI, especially through its Sindex metric. Further studies will be required to more directly establish the potential of diffusion MRI to monitor the glymphatic system. Due to its complete non-invasiveness, this new approach could be used for clinical studies to confirm or infirm the existence of such a glymphatic system in humans \[[@pone.0229702.ref024]\].

Supporting information {#sec014}
======================

###### 

Boxplot and time course of Sindex in the DG (a: boxplot, b: time course) and in the CA3 (c: boxplot, d: time course). Boxplot and time course of sADC in the DG (e: boxplot, f: time course) and in the CA3 (g: boxplot, h: time course). Left, Vehicle group; right TGN-020 group in each figure. Pre, pre-injection (light blue); post, post-injection (dark blue) of vehicle or TGN-020 group in boxplot. \*: p\<0.05, \*\*: p\<0.01, \*\*\*: p\<0.001 are the result for the paired t-test between pre and post-injection for each group. +: p\<0.05, ++: p\<0.01, +++: p\<0.001 are the result for a t-test with posthoc correction for multiple comparison between post-injection of the two groups. Diamonds represent outliers, a point is defined as an outlier if its value is below Q1--1.5×IQR or above Q3 + 1.5×IQR, where Q1 is the first quartile, Q3 the third quartile and IQR the interquartile range. Blue line is vehicle group and orange line is TGN-020 group. Error bar shows standard deviation. The dashed line represents the injection time. +: p\<0.05, ++: p\<0.01, +++: p\<0.001 by two sample t-test between the two groups for each time point. Note: The voxel count in DG was very small (85 versus 181 in CA3) resulting in very noisy data. The apparent significant difference in sADC and Sindex values between the TGN-020 and saline groups one point before baseline (b, f) might result from an underestimation of the standard-deviation. The difference becomes largely more significant after injections, overcoming any uncertainty in standard-deviation estimates.

(TIF)

###### 

Click here for additional data file.
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The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Authors presented a very interesting study, evaluating the utility of diffusion MRI to map glymphatic function, through the modification of the AQP4 expression. This is of high scientific and clinical value, very timely and of high impact.

The experiment is well designed, and the execution is sound. This reviewer has below comments regarding the validity and conclusions. Figures quality/dpi are low!

Major comments:

1\. The main limitation is interpreting diffusion measures as glymphatic system function. AQP4 is also involved in brain inflammation and regulation of extracellular space volume. How do you know that the observed diffusion changes are related to the glymphatic system?

Even though authors were cautious about the interpretation of their results, they should probably discuss other potential explanations for their findings and adjust their main conclusion accordingly.

2\. Authors reported significant differences in both CA3 and DG of the TGN-020 group. How do you explain the DG change, given the mentioned AQP4 abundant?

3\. Regarding above comment: Do you have the data (for example SWI or high resolution T2) to identify regions with high vascular presence to look at the S_i and sADC changes on those area? That could potentially help identify the underlying AQP4 involvement.

4\. Based on ref \[36\]: "AQP4 protein levels were highest in the cerebellum with lower expression in the cortex and hippocampus." This suggests that the cerebellum should have been a major ROI in this study. Why cerebellum is not included?

5\. Figures have extremely low quality (for example Figures 4 and 5). I could only guess the labels and axes.

6\. It seems rather strange to have (significant) differences prior to injection (e.g. Fig 5.h)? This needs to be addressed. One would expect to see no difference whatsoever.

7\. In favor with reported findings, below paper showed that diffusion MRI is affected by perivascular space fluid presence, which should be cited:

Sepehrband, F., Cabeen, R. P., Choupan, J., Barisano, G., Law, M., Toga, A. W., & Alzheimer\'s Disease Neuroimaging Initiative. (2019). Perivascular space fluid contributes to diffusion tensor imaging changes in white matter. NeuroImage, 197, 243-254.

8\. Not in favor of reported finding, below study reported "we failed to detect a significant change in the brain extracellular water volume using diffusion weighted imaging in awake and anesthetized mice." This paper also should be cited/discussed:

Gakuba, C., Gaberel, T., Goursaud, S., Bourges, J., Di Palma, C., Quenault, A., \... & Gauberti, M. (2018). General anesthesia inhibits the activity of the "glymphatic system". Theranostics, 8(3), 710.

9\. Another paper that links diffusion changes to glymphatic system is below, which also could be cited:

Thomas, C., Sadeghi, N., Nayak, A., Trefler, A., Sarlls, J., Baker, C. I., & Pierpaoli, C. (2018). Impact of time-of-day on diffusivity measures of brain tissue derived from diffusion tensor imaging. Neuroimage, 173, 25-34.

A minor comment:

1\. Page 11, line 251: "peculiar to this this brain" -\> "peculiar to this brain"

2\. Please report the age of the mice, in each group (maybe it is reported somewhere, but I couldn't find it).

Reviewer \#2: In this paper the dynamic changes of astrocyte activity were investigated using DWI in 32 mice by inhibiting AQP4 channels with a TGN-020 solution. Two novel DWI measures were used to study the results which show a significant decrease in the Sindex, a diffusion marker of tissue microstructure, and a significant increase of the water diffusion coefficient (sADC) in cerebral cortex and hippocampus compared to saline injection.

Developing reliable non-invasive biomarkers for the glymphatic system is important for translational studies. This study has done a great job to introduce such biomarkers. However, it may need some more work to improve the study.

Major points:

1- In addition to sindex, the authors could use FA for comparison or at least confirming (in a few sentences) that FA is not showing the trend seen in sindex.

2- Why mice were chosen? Rats have bigger brain and therefore the imaging could be easier.

3- Histology analyses of the mice after imaging could be so helpful in confirming the study outcomes.

Minor points:

Line 16: "We assumed no change of position among the different scans during acquisitions for each mouse and geometric distortion with b values to be negligible; this condition was qualitatively checked on several mice." Why not using motion correction to compensate for animal movement during the imaging?

Line 119: "Furthermore, signal instabilities were quantitatively evaluated for each subject and subjects exhibiting instabilities above 4% for most voxels were eliminated." Could you please explain more?

Line 156: Please mention in Fig3 caption the time point of the displayed maps? I assume the maps correspond to the averaged 6 time points of the pre injection and the last 6 time points after the injection.

Line 251: There is an extra "this".

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0229702.r002

Author response to Decision Letter 0

10 Apr 2020

Editor comment

1\. How do you know that the observed diffusion changes are related to the glymphatic system?

The existence of the glymphatic system is controversial. Our results do not aim at demonstrating the existence or not of a glymphatic system. However, if we admit that such a system exists it has been strongly suggested in the literature (REF XXX) that astrocytes must play a major role, and, in turn, AQP4 channels expressed by astrocytes. The aim of our work is to show that the modulation of astrocyte activity by TGN-020 which is known as a AQP4 channel blocker can be monitored with diffusion MRI and in particular the Sindex, that's all. The Discussion and Conclusion have been revised to make this point clear.

2\. How do you explain the DG change, given the mentioned AQP4 abundant?

The density of AQP4 receptors in DG is higher than in the other regions we have investigated. Indeed, the larger sADC and Sindex change observed in DG under TGN-020 administration is an indirect proof that TGN-020 acted on astrocyte AQP4 channels. The Discussion has been revised accordingly.

3\. Do you have the data to identify regions with high vascular presence to look at the Si and sADC changes on those area?

A relevant parameter could be, indeed, the density of small vessels. Such vessels are not visible even within the high resolution T2-weighted images we acquired using Turbo RARE (see Methods and Figure 2). Such vessels would require the additional acquisition of perfusion MRI data, such as IVIM MRI, which could not be done during the acquisition time window our anesthetic protocol permitted. Hence, we relied on previous studies reporting the vascular distribution across brain structures using microscopy (ref 40).

4\. In addition to sindex, the authors could use FA for comparison.

FA is relevant to assess diffusion anisotropy which is present only in whiter matter at the resolution of our images (not in the cortex). The Sindex (and the sADC) is a much more relevant parameter. Furthermore, as explained in a recent article (Iima at al. European Radiology, 2020), FA values are highly sensitive to noise and, in turn, to ADC (or sADC) values. Variations in FA would thus reflect the changes we have observed in sADC values more than genuine changes in diffusion anisotropy.

Journal Requirements

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. Thank you for including your ethics statement:

i\) Please amend your current ethics statement to include the full name of the ethics committee that approved your specific study.

ii\) Once you have amended this/these statement(s) in the Methods section of the manuscript, please add the same text to the "Ethics Statement" field of the submission form (via "Edit Submission").

For additional information about PLOS ONE submissions requirements for ethics oversight of animal work, please refer to <http://journals.plos.org/plosone/s/submission-guidelines#loc-animal-research>

We initially refrained to provide information which could potentially conflict with an anonymous review. Full details have been added in the Methods section.

Response to reviewers

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Authors presented a very interesting study, evaluating the utility of diffusion MRI to map glymphatic function, through the modification of the AQP4 expression. This is of high scientific and clinical value, very timely and of high impact.

The experiment is well designed, and the execution is sound. This reviewer has below comments regarding the validity and conclusions. Figures quality/dpi are low!

Major comments:

1\. The main limitation is interpreting diffusion measures as glymphatic system function. AQP4 is also involved in brain inflammation and regulation of extracellular space volume. How do you know that the observed diffusion changes are related to the glymphatic system?

Even though authors were cautious about the interpretation of their results, they should probably discuss other potential explanations for their findings and adjust their main conclusion accordingly.

The existence of the glymphatic system is controversial. Our results do not aim at demonstrating the existence or not of a glymphatic system. However, if we admit that such a system exists it has been strongly suggested in the literature (Illif et al, Sci Transl Med, 2012,) that astrocytes must play a major role system (Mestre et al, eLife, 2018), and, in turn, AQP4 channels expressed by astrocytes (Ikeshima-Kataoka et al, Int J Mol Sci, 2016). The aim of our work is to show that the modulation of astrocyte activity by TGN-020 which is known as a AQP4 channel blocker can be monitored with diffusion MRI and in particular the Sindex, that's all. Further studies will be required to establish the potential of diffusion MRI to monitor the glymphatic system. The Discussion and Conclusion have been revised to make this point clear.

2\. Authors reported significant differences in both CA3 and DG of the TGN-020 group. How do you explain the DG change, given the mentioned AQP4 abundant?

The density of AQP4 receptors in DG is higher than in the other regions we have investigated (Hsu et al, Neuroscience, 2011; Hubbard et al, ASN Neuro, 2015). Indeed, the larger sADC and Sindex change observed in DG under TGN-020 administration is an indirect proof that TGN-020 acted on astrocyte AQP4 channels. However, as we explain in the response to comment\#6, the baseline of DG was not stable due to the smaller voxel size. We need higher resolution image for the validation of Sindex changes in DG. The Discussion has been revised accordingly.

3\. Regarding above comment: Do you have the data (for example SWI or high resolution T2) to identify regions with high vascular presence to look at the S_i and sADC changes on those area? That could potentially help identify the underlying AQP4 involvement.

We agree that a relevant parameter could be, indeed, the density of small vessels. Such vessels are not visible even within the high resolution T2-weighted images we acquired using Turbo RARE (see Methods and Figure 2). Such vessels would require the additional acquisition of perfusion MRI data, such as IVIM MRI, which could not be done during the acquisition time window our anesthetic protocol permitted. Hence, we relied on previous studies reporting the vascular distribution across brain structures using microscopy (Xiong et al, Front Neuroanat, 2017).

4\. Based on ref \[36\]: "AQP4 protein levels were highest in the cerebellum with lower expression in the cortex and hippocampus." This suggests that the cerebellum should have been a major ROI in this study. Why cerebellum is not included?

We did not have a full brain coverage including the cerebellum due to the limitation of the scanning time (scanning time is determined by number of slices). Instead, we investigated the hippocampus because AQP4 expresses abundantly in this region (Hsu et al, Neuroscience, 2011; Hubbard et al, ASN Neuro, 2015).

5\. Figures have extremely low quality (for example Figures 4 and 5). I could only guess the labels and axes.

We are sorry for the very low quality of Figure 4 and 5 which probably resulted from the PDF conversion. Revised figures were uploaded after checking quality with the digital diagnostic tool of PLOS: , <https://pacev2.apexcovantage.com/>.

6\. It seems rather strange to have (significant) differences prior to injection (e.g. Fig 5.h)? This needs to be addressed. One would expect to see no difference whatsoever.

Because the volume of DG is smaller than cerebral cortex and striatum, the Sindex and sADC in DG were noisier rather than these regions. (The number of voxel size in DG, CA3, hippocampus, striatum, cortex is respectively: 85, 181, 763, 2069 and 8270) This is the reason why baseline of Sindex and sADC in DG was not stable. We decided to move DG and CA3 from the manuscript to supplementary data, instead we have used whole hippocampal region for the main figure. We described the instability in DG and CA3 in the Results section.

7\. In favor with reported findings, below paper showed that diffusion MRI is affected by perivascular space fluid presence, which should be cited:

Sepehrband, F., Cabeen, R. P., Choupan, J., Barisano, G., Law, M., Toga, A. W., & Alzheimer\'s Disease Neuroimaging Initiative. (2019). Perivascular space fluid contributes to diffusion tensor imaging changes in white matter. NeuroImage, 197, 243-254.

We have added this reference in Introduction (Reference 26).

8\. Not in favor of reported finding, below study reported "we failed to detect a significant change in the brain extracellular water volume using diffusion weighted imaging in awake and anesthetized mice." This paper also should be cited/discussed:

Gakuba, C., Gaberel, T., Goursaud, S., Bourges, J., Di Palma, C., Quenault, A., \... & Gauberti, M. (2018). General anesthesia inhibits the activity of the "glymphatic system". Theranostics, 8(3), 710.

This article compared the ADC and intracerebral accumulation of DOTA-Gd injected in intracisternal site in awaked and anesthetized state. The suppressed accumulation of DOTA-Gd was observed in anesthetized state compared with awaked state, while ADC was not changed between awaked and anesthetized sate. The DOTA-Gd increased the SNR when they accumulated for long time (30-60 min for accumulation in the study) and acquisition has been done under anesthesia. In contrast, diffusion MRI has been performed in awaked and anesthetized condition. The diffusion MRI could be influenced by the head motion and respiration, which could be more significant in awaked state. This potentially interferes ADC measurement to reduce the sensitivity. Further study to improve the sensitivity is required to assess the potential of diffusion MRI to detect the awaked and anesthetized state. We have described this article in Discussion.

9\. Another paper that links diffusion changes to glymphatic system is below, which also could be cited:

Thomas, C., Sadeghi, N., Nayak, A., Trefler, A., Sarlls, J., Baker, C. I., & Pierpaoli, C. (2018). Impact of time-of-day on diffusivity measures of brain tissue derived from diffusion tensor imaging. Neuroimage, 173, 25-34.

We thank for these valuable references. We agree that those references would be helpful for the readers to better understand and appreciate our results. This has been cited as reference 27.

A minor comment:

1\. Page 11, line 251: "peculiar to this this brain" -\> "peculiar to this brain"

We have corrected this typo.

2\. Please report the age of the mice, in each group (maybe it is reported somewhere, but I couldn't find it).

We used the mice aged 4-10 weeks in each group. The age of mice has been added into the Material and Methods part of the manuscript.

Reviewer \#2: In this paper the dynamic changes of astrocyte activity were investigated using DWI in 32 mice by inhibiting AQP4 channels with a TGN-020 solution. Two novel DWI measures were used to study the results which show a significant decrease in the Sindex, a diffusion marker of tissue microstructure, and a significant increase of the water diffusion coefficient (sADC) in cerebral cortex and hippocampus compared to saline injection.

Developing reliable non-invasive biomarkers for the glymphatic system is important for translational studies. This study has done a great job to introduce such biomarkers. However, it may need some more work to improve the study.

Major points:

1- In addition to sindex, the authors could use FA for comparison or at least confirming (in a few sentences) that FA is not showing the trend seen in sindex.

FA is relevant to assess diffusion anisotropy which is present only in whiter matter at the resolution of our images. The Sindex (and the sADC) is a much more relevant parameter. Furthermore, as explained in a recent article (Iima at al. European Radiology, 2020), FA values are highly sensitive to noise and, in turn, to ADC (or sADC) values. Variations in FA would thus reflect the changes we have observed in sADC values more than genuine changes in diffusion anisotropy.

2- Why mice were chosen? Rats have bigger brain and therefore the imaging could be easier.

We chose mice instead of rats because our diffusion MRI protocol could be applicable in the future to investigate AQP-4 KO mice. There is no such transgenic model for rats. Also, our MRI setup includes a cryoprobe dedicated to mouse head imaging, which increases the SNR and contrast. This specific coil is too small for rat heads.

3- Histology analyses of the mice after imaging could be so helpful in confirming the study outcomes.

We agree that histology would have been a nice addition to confirm volume changes of astrocytes in the different groups (TGN-020 group and vehicle group). However, such tests require the brain to be fixed, hence they cannot be performed to check volume changes before and after TGN-020 (or saline) injection within the same animal. Another method to monitor astrocyte volume could be in vivo fluorescent imaging, but this method can be applied only in the cortex. Those issues have been added to the Discussion.

Minor points:

Line 16: "We assumed no change of position among the different scans during acquisitions for each mouse and geometric distortion with b values to be negligible; this condition was qualitatively checked on several mice." Why not using motion correction to compensate for animal movement during the imaging?

Motion correction is tricky when considering quantitative diffusion MRI as motion algorithms work on the reconstructed images. Especially, as acquisitions are performed with specific orientations of the diffusion-probing gradient pulses in space any rotation in the reconstructed images would not reflect genuine signal changes which would have occurred if the diffusion-probing gradient pulses had rotated in the same way. Instead, we decided to simply reject data sets were motion was too large (\>4%) using a semi-quantitative index based on signal stability across successive scans. We agree that the text was not clear and we have revised it.

Line 119: "Furthermore, signal instabilities were quantitatively evaluated for each subject and subjects exhibiting instabilities above 4% for most voxels were eliminated." Could you please explain more?

The standard-deviation of the signal intensity across scans was evaluated for each b value and each voxel (after Gaussian smoothing) was estimated. A threshold of 4% was used flag unstable voxels. . Data sets were one of the ROIs have only flagged voxels were discarded.

Line 156: Please mention in Fig3 caption the time point of the displayed maps? I assume the maps correspond to the averaged 6 time points of the pre injection and the last 6 time points after the injection.

We have added in the legend of the figure 3 that the maps correspond to the mean of the 6 last time points.

Line 251: There is an extra "this".

We have corrected this typo.
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Diffusion MRI reveals in vivo and non-invasively changes in astrocyte function induced by an aquaporin-4 inhibitor.

PLOS ONE

Dear Pr. Le Bihan,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please response reviewer\'s minor question.

We would appreciate receiving your revised manuscript by May 27 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Quan Jiang, Ph,D.

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: I Don\'t Know

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Authors responded to the raised issues and addressed reviewer's concern.

One point that remained unaddressed is the general assumption. The author states that "The aim of our work is to show that the modulation of astrocyte activity by TGN-020 which is known as a AQP4 channel blocker can be monitored with diffusion MRI and in particular the Sindex, that's all."

But throughout the paper the text suggests that that's not all. For example, the abstract says

"The Glymphatic System (GS) has been proposed as a mechanism to clear brain tissue from waste. Its dysfunction might lead to several brain pathologies, including the Alzheimer'disease. A key component of the GS and brain tissue water circulation is the astrocyte which is regulated by acquaporin-4 (AQP4), a membrane-bound water channel on the astrocytic end-feet."

Well, clearly the author is relating this to glymphatic system. Yet, relating this to glymphatic system is not the main concern. If one can measure astrocyte activity, it's not unreasonable to relate it to glymphatic system. The main concern is that AQP-4 is not only involved in modulation of astrocyte activity. It is also involved in the brain inflammatory response and also in the regulation of the extracellular volume. Both of these could affect diffusion signal. Blocking AQP-4 could lead to inflammation or changes in the extracellular fluid which affect the diffusion signal. Therefore, what you observe here may have nothing to do with the astrocyte activity. This limitation should be addressed.

PS. Regarding DG, if the data is noisy, it should lead to higher standard deviation not a systematic group mean difference.

Reviewer \#2: The authors resolved well my concerns about their work and made the manuscript more clear. I have no other question to add.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Author response to Decision Letter 1

28 Apr 2020

Reviewer \#1: Authors responded to the raised issues and addressed reviewer's concern.

One point that remained unaddressed is the general assumption. The author states that "The aim of our work is to show that the modulation of astrocyte activity by TGN-020 which is known as a AQP4 channel blocker can be monitored with diffusion MRI and in particular the Sindex, that's all."

But throughout the paper the text suggests that that's not all. For example, the abstract says

"The Glymphatic System (GS) has been proposed as a mechanism to clear brain tissue from waste. Its dysfunction might lead to several brain pathologies, including the Alzheimer'disease. A key component of the GS and brain tissue water circulation is the astrocyte which is regulated by acquaporin-4 (AQP4), a membrane-bound water channel on the astrocytic end-feet."

Well, clearly the author is relating this to glymphatic system. Yet, relating this to glymphatic system is not the main concern. If one can measure astrocyte activity, it's not unreasonable to relate it to glymphatic system. The main concern is that AQP-4 is not only involved in modulation of astrocyte activity. It is also involved in the brain inflammatory response and also in the regulation of the extracellular volume. Both of these could affect diffusion signal. Blocking AQP-4 could lead to inflammation or changes in the extracellular fluid which affect the diffusion signal. Therefore, what you observe here may have nothing to do with the astrocyte activity. This limitation should be addressed.

PS. Regarding DG, if the data is noisy, it should lead to higher standard deviation not a systematic group mean difference

� The statement about the Glymphatic System in the abstract and the introduction is only to explain our general motivation to conduct our study of the potential of diffusion MRI to monitor astrocyte activity. It is not a claim that the GS exists (we believe we have been careful in the manuscript about this fact). We only briefly review the literature to shade light on the context of the study and indicate why investigating astrocyte activity might be important. We are aware that TGN-020 effects are not specific to astrocytes, as stated in the manuscript. Effects on the brain inflammatory response can be discarded given the time course of the effects we have observed. Regarding the extracellular space (ISF) effects on the diffusion MRI would result only from changes in diffusion hindrance/tortuosity (fluid flow is well too slow to result in IVIM effects, this has been shown by other groups, furthermore the Sindex was purposely calculated using the lowest key b value 250s/mm² to make residual IVIM effects completely negligible). Hence, variations in extracellular space shape and volume only reflect changes in the local cellular background (a kind of negative imprint). The decrease in Sindex (and sADC increase) points out to decrease in the amount of diffusion hindrance from astrocytes (which is by far the dominant cell type in the regions where we observed the largest response). As stated in the discussion "Based on established diffusion MRI mechanisms \[28\] this hindrance decrease suggests an astrocyte volume reduction \[43,44\] associated with an increase of the ISF (were diffusion is tortuous) \[45\] or an increase in astrocyte membrane permeability and water exchange". We believe that this statement about the mechanism leading to our observation is correct and broad enough, and the manuscript was not changed.

� Regarding the DG, the data are, indeed, very noisy given the very small voxel count. The apparent group difference may just be coincidental as the standard-deviation cannot be accurately estimated precisely given the small voxel count. We realize that this might be puzzling, but, for scientific integrity, we decided not to "hide" those results but to show them. A note has been added to the caption of SuppL Fig.1.
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